Celsion (NASDAQ: CLSN) and Alder BioPharmaceuticals (NASDAQ:ALDR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.
This table compares Celsion and Alder BioPharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Celsion and Alder BioPharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Alder BioPharmaceuticals||$110,000.00||10,361.02||-$156.25 million||($5.37)||-3.13|
Celsion has higher revenue and earnings than Alder BioPharmaceuticals. Alder BioPharmaceuticals is trading at a lower price-to-earnings ratio than Celsion, indicating that it is currently the more affordable of the two stocks.
This is a summary of current recommendations and price targets for Celsion and Alder BioPharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Celsion currently has a consensus target price of $14.50, suggesting a potential upside of 443.07%. Alder BioPharmaceuticals has a consensus target price of $30.42, suggesting a potential upside of 81.05%. Given Celsion’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Celsion is more favorable than Alder BioPharmaceuticals.
Institutional & Insider Ownership
4.0% of Celsion shares are held by institutional investors. Comparatively, 96.8% of Alder BioPharmaceuticals shares are held by institutional investors. 3.8% of Celsion shares are held by company insiders. Comparatively, 10.6% of Alder BioPharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility & Risk
Celsion has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Alder BioPharmaceuticals has a beta of 2.48, indicating that its stock price is 148% more volatile than the S&P 500.
Alder BioPharmaceuticals beats Celsion on 8 of the 14 factors compared between the two stocks.
Celsion Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).
Alder BioPharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder’s third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.